Research ArticleOriginal Article
Open Access

Molecular subtyping of mammary Paget’s disease using immunohistochemistry

Maria Arafah, Shoukat A. Arain, Emad M. Said Raddaoui, Asma Tulba, Fatimah H. Alkhawaja and Ahlam Al Shedoukhy
Saudi Medical Journal May 2019, 40 (5) 440-446; DOI: https://doi.org/10.15537/smj.2019.5.23967

References

  1. ↵
    1. Arpino G,
    2. Milano M,
    3. De Placido S
    (2015) Features of aggressive breast cancer. Breast 24:594–600.
    OpenUrl
  2. ↵
    1. Alabdulkarim B,
    2. Hassanain M,
    3. Bokhari A,
    4. AlSaif A,
    5. Alkarji H
    (2018) Age distribution and outcomes in patients undergoing breast cancer resection in Saudi Arabia. A single-institute study. Saudi Med J 39:464–469.
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Prat A,
    2. Pineda E,
    3. Adamo B,
    4. Galván P,
    5. Fernández A,
    6. Gaba L,
    7. et al.
    (2015) Clinical implications of the intrinsic molecular subtypes of breast cancer. Breast 24(Suppl 2):S26–S35.
    OpenUrlCrossRefPubMed
  4. ↵
    (2012) Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 490:61–70.
    OpenUrlCrossRefPubMedWeb of Science
  5. ↵
    1. Perou CM,
    2. Sørlie T,
    3. Eisen MB,
    4. van de Rijn M,
    5. Jeffrey SS,
    6. Rees CA,
    7. et al.
    (2000) Molecular portraits of human breast tumours. Nature 406:747–752.
    OpenUrlCrossRefPubMedWeb of Science
  6. ↵
    1. Viale G
    (2012) The current state of breast cancer classification. Ann Oncol 23(Suppl 10):x207–x210.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Goldhirsch A,
    2. Winer EP,
    3. Coates AS,
    4. Gelber RD,
    5. Piccart-Gebhart M,
    6. Thürlimann B,
    7. et al.
    (2013) Personalizing the treatment of women with early breast cancer:highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 24:2206–2223.
    OpenUrlCrossRefPubMedWeb of Science
  8. ↵
    1. Rouzier R,
    2. Perou CM,
    3. Symmans WF,
    4. Ibrahim N,
    5. Cristofanilli M,
    6. Anderson K,
    7. et al.
    (2005) Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Research 11:678–685.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Cheang MC,
    2. Chia SK,
    3. Voduc D,
    4. Gao D,
    5. Leung S,
    6. Snider J,
    7. et al.
    (2009) Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 101:736–750.
    OpenUrlCrossRefPubMedWeb of Science
  10. ↵
    1. Chaudary MA,
    2. Millis RR,
    3. Lane EB,
    4. Miller NA
    (1986) Paget's disease of the nipple:a ten-year review including clinical, pathological, and immunohistochemical findings. Breast Cancer Res Treat 8:139–46.
    OpenUrlCrossRefPubMedWeb of Science
  11. ↵
    1. Paget J
    (1971) On disease of the mammary areola preceding cancer of the mammary gland. Cancer J Clin 21:303–304.
    OpenUrl
  12. ↵
    1. Alnegheimish NA,
    2. Alshatwi RA,
    3. Alhefdhi RM,
    4. Arafah MM,
    5. AlRikabi AC,
    6. Husain S
    (2016) Molecular subtypes of breast carcinoma in Saudi Arabia. A retrospective study. Saudi Med J 37:506–512.
    OpenUrlAbstract/FREE Full Text
  13. ↵
    1. Sengal AT,
    2. Haj-Mukhtar NS,
    3. Elhaj AM,
    4. Bedri S,
    5. Kantelhardt EJ,
    6. Mohamedani AA
    (2017) Immunohistochemistry defined subtypes of breast cancer in 678 Sudanese and Eritrean women;hospitals based case series. BMC Cancer 17:804.
    OpenUrlPubMed
  14. ↵
    1. AlZaman AS,
    2. Mughal SA,
    3. AlZaman YS,
    4. AlZaman ES
    (2016) Correlation between hormone receptor status and age, and its prognostic implications in breast cancer patients in Bahrain. Saudi Med J 37:37–42.
    OpenUrlAbstract/FREE Full Text
  15. ↵
    1. Fu W,
    2. Lobocki CA,
    3. Silberberg BK,
    4. Chelladurai M,
    5. Young SC
    (2001) Molecular Markers in Paget Disease of the Breast. J Surg Oncol 77:171–178.
    OpenUrlCrossRefPubMedWeb of Science
  16. ↵
    1. Dittmar T,
    2. Husemann A,
    3. Schewe Y,
    4. Nofer JR,
    5. Niggemann B,
    6. Zänker KS,
    7. et al.
    (2002) Induction of cancer cell migration by epidermal growth factor is initiated by specific phosphorylation of tyrosine 1248 of c-erbB-2 receptor via EGFR. FASEB J 16:1823–1825.
    OpenUrlCrossRefPubMed
  17. ↵
    1. Wolff AC,
    2. Hammond MEH,
    3. Allison KH,
    4. Harvey BE,
    5. Mangu PB,
    6. Bartlett JMS,
    7. et al.
    (2018) Human epidermal growth factor receptor 2 testing in breast cancer:American Society of Clinical Oncology/College of American Pathologists clinical practice guideline focused update. J Clin Oncol 36:2105–2122.
    OpenUrlCrossRefPubMed
  18. ↵
    1. Merrill AY,
    2. White A,
    3. Howard-McNatt M
    (2017) Paget's Disease of the Breast:An Institutional Review and Surgical Management. Am Surg 83:e96–98.
    OpenUrl
  19. ↵
    1. Sek P,
    2. Zawrocki A,
    3. Biernat W,
    4. Piekarski JH
    (2010) HER2 molecular subtype is a dominant subtype of mammary Paget's cells. An immunohistochemical study. Histopathology 57:564–571.
    OpenUrlCrossRefPubMedWeb of Science
  20. ↵
    1. Mai KT,
    2. Yazdi HM,
    3. Perkins DG
    (1999) Mammary Paget's disease:evidence of diverse origin of the disease with a subgroup of Paget's disease developing from the superficial portion of lactiferous duct and a discontinuous pattern of tumor spread. Pathol Int 49:956–961.
    OpenUrlPubMed
  21. ↵
    1. Sandoval-Leon AC,
    2. Drews-Elger K,
    3. Gomez-Fernandez CR,
    4. Yepes MM,
    5. Lippman ME
    (2013) Paget's disease of the nipple. Breast Cancer Res Treat 141:1–12.
    OpenUrlCrossRefPubMed
  22. ↵
    1. Chen CY,
    2. Sun LM,
    3. Anderson BO
    (2006) Paget disease of the breast:changing patterns of incidence, clinical presentation, and treatment in the U.S. Cancer 107:1448–1458.
    OpenUrlCrossRefPubMedWeb of Science
  23. ↵
    1. Onoe S,
    2. Kinoshita T,
    3. Tamura N,
    4. Nagao T,
    5. Kuno H,
    6. Hojo T,
    7. et al.
    (2011) Feasibility of breast conserving surgery for Paget's disease. Breast 20:515–518.
    OpenUrlPubMed
  24. ↵
    1. Song Q,
    2. Jin Y,
    3. Huang T,
    4. Zhang JH
    (2015) Diagnosis and treatment of Paget's disease of the breast:an analysis of 72 cases. Int J Clin Exp Med 8:19616–19620.
    OpenUrl
  25. ↵
    1. Lester T,
    2. Wang J,
    3. Bourne P,
    4. Yang Q,
    5. Fu L,
    6. Tang P
    (2009) Different panels of markers should be used to predict mammary Paget's disease associated with in situ or invasive ductal carcinoma of the breast. Ann Clin Lab Sci 39:17–24.
    OpenUrlAbstract/FREE Full Text
  26. ↵
    1. Kothari AS,
    2. Beechey-Newman N,
    3. Hamed H,
    4. Fentiman IS,
    5. D'Arrigo C,
    6. Hanby AM,
    7. et al.
    (2002) Paget disease of the nipple:a multifocal manifestation of higher-risk disease. Cancer 95:1–7.
    OpenUrlCrossRefPubMed
  27. ↵
    1. Yip CH,
    2. Rhodes A
    (2014) Estrogen and progesterone receptors in breast cancer. Future Oncol 10:2293–2301.
    OpenUrl
  28. ↵
    1. Ling H,
    2. Hu X,
    3. Xu XL,
    4. Liu ZB,
    5. Shao ZM
    (2013) Patients with nipple-areola Paget's disease and underlying invasive breast carcinoma have very poor survival:a matched cohort study. PLoS One 8:e61455.
    OpenUrl
  29. ↵
    1. Wachter DL,
    2. Wachter PW,
    3. Fasching PA,
    4. Beckmann MW,
    5. Hack CC,
    6. Riener MO,
    7. et al.
    (2019) Characterization of molecular subtypes of paget disease of the breast using immunohistochemistry and in situ hybridization. Arch Pathol Lab Med 143:206–211.
    OpenUrl
  30. ↵
    1. Hammond ME,
    2. Hayes DF,
    3. Dowsett M,
    4. Allred DC,
    5. Hagerty KL,
    6. Badve S,
    7. et al.
    (2010) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med 134:e48–72.
    OpenUrlPubMedWeb of Science
  31. ↵
    1. Dai X,
    2. Xiang L,
    3. Li T,
    4. Bai Z
    (2016) Cancer hallmarks, biomarkers and breast cancer molecular subtypes. J Cancer 7:1281–1294.
    OpenUrlCrossRef
  32. ↵
    1. Liegl B,
    2. Horn LC,
    3. Moinfar F
    (2005) Androgen receptors are frequently expressed in mammary and extramammary Paget's disease. Mod Pathol 18:1283–1288.
    OpenUrlCrossRefPubMedWeb of Science
  33. ↵
    1. Bianco MK,
    2. Vasef MA
    (2006) HER-2 gene amplification in Paget disease of the nipple and extramammary site:a chromogenic in situ hybridization study. Diagn Mol Pathol 15:131–135.
    OpenUrlCrossRefPubMedWeb of Science
  34. ↵
    1. Chen C,
    2. Peng J,
    3. Xia HS,
    4. Yang GF,
    5. Wu QS,
    6. Chen LD,
    7. et al.
    (2009) Quantum dots-based immunofluorescence technology for the quantitative determination of HER2 expression in breast cancer. Biomaterials 30:2912–2918.
    OpenUrlCrossRefPubMed
  35. ↵
    1. Gupta P,
    2. Rai NN,
    3. Agarwal L,
    4. Namdev S
    (2018) Comparison of molecular subtypes of carcinoma of the breast in two different age groups:a single institution experience. Cureus 10:e2834.
    OpenUrl
  36. ↵
    1. Kurebayashi J,
    2. Moriya T,
    3. Ishida T,
    4. Hirakawa H,
    5. Kurosumi M,
    6. Akiyama F,
    7. et al.
    (2007) The prevalence of intrinsic subtypes and prognosis in breast cancer patients of different races. Breast 16(Suppl 2):S72–7.
    OpenUrlCrossRefPubMedWeb of Science
  37. ↵
    1. Rahmawati Y,
    2. Setyawati Y,
    3. Widodo I,
    4. Ghozali A,
    5. Purnomosari D
    (2018) Molecular subtypes of indonesian breast carcinomas - lack of association with patient age and tumor size. Asian Pac J Cancer Prev 19:161–166.
    OpenUrl
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools
Bookmark this article

Jump to section